top of page

Autoimmunity Modifying (AIM) Biologicals
Targeted, highly specific autoimmunity modifying therapeutics for
NMOSD and Parkinson’s

AIM Biologicals (AutoImmunity Modifying Biologicals) utilize a novel mechanism where peptide antigens presented on immunosuppressive MHC class I molecules are designed to selectively and efficiently induce antigen-specific tolerance. Based on this mechanism, the targeted immunomodulating therapeutics are being designed as optimized soluble molecules with the goal to selectively induce tolerance to various autoantigens.

During pregnancy, the maternal immune system tolerates paternal antigens from the embryo but is still effective to protect mother and embryo from foreign antigens. Parts of the natural mechanisms responsible for this feto-maternal immune tolerance form the scientific basis for the concept of AIM Biologicals.

​

Platform Technology Enabling Highly Specific Treatments for Auto-Immune Diseases with Well-Defined Target Antigens

MHC class 1 molecules (HLA-G)

Mechanism based on the immune tolerance induced by maternal immune system during pregnancy to protect fetus

Application Across Multiple Indications

Ability to optimize with disease-specific antigen to induce immune tolerance

Image created with BioRender.com

Selective Treatment Option for Neuromyelitis Optica Spectrum Disorder (NMOSD)

  • Well-defined antigen: Aquaporin-4 (AQP4) 

  • NMOSD is a seriously debilitating and often fatal, auto-antibody mediated inflammatory CNS orphan disorder with significant unmet medical need affecting 1-5 per 100,000 people 

  • Entered into an R&D agreement with Massachusetts General Hospital (MGH) in Boston and
    Dr. Michael Levy, a worldwide leading NMOSD expert 

​

​

Treatment of Parkinson's Disease

  • Growing evidence suggests that PD could be considered as an autoimmune disease1 

  • Targeting α-Synuclein (α-Syn), hallmark for degeneration of dopaminergic neurons in the substantia nigra (SN) 

  • Total addressable market of over ~9 million people2 

​

1: Bonam et al.; Autoimmunity Reviews 2020 
2: World Health Organization. (n.d.). Parkinson disease. World Health Organization 

bottom of page